Clinical Trial Update: Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial update on secured access to vemurafenib for patients with tumors harboring BRAF alterations; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancers
• Hematologic Cancers
• Solid Tumors

Drugs mentioned

• Zelboraf (vemurafenib)

Snippet

Sponsor: UNICANCER | Conditions: Solid Tumors, Hematologic Cancers | Phase 2 | Status: ACTIVE_NOT_RECRUITING